

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5620813

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
AKIRA SUGIYAMA	10/13/2016
HIROFUMI DOI	10/14/2016
TATSUHIKO KODAMA	10/13/2016
TSUYOSHI INOUE	10/15/2016
EIICHI MIZOHATA	10/14/2016
TATSUYA KAWATO	10/14/2016
TOMOHIRO MESHIZUKA	10/17/2016
MOTOMU KANAI	10/14/2016
YOHEI SHIMIZU	10/14/2016
NORIAKI TAKASU	10/14/2016
MARI TAKATSU	10/18/2016

RECEIVING PARTY DATA

Name:	SAVID THERAPEUTICS INC.
Street Address:	2-1-11, KACHIDOKI, CHUO-KU
City:	TOKYO
State/Country:	JAPAN
Postal Code:	104-0054

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16512894

CORRESPONDENCE DATA

Fax Number: (703)716-1180

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7037161191

Email: gbpatent@gbpatent.com

Correspondent Name: GREENBLUM AND BERNSTEIN, P.L.C.

Address Line 1: 1950 ROLAND CLARKE PLACE

Address Line 4: RESTON, VIRGINIA 20191

ATTORNEY DOCKET NUMBER:	P56604
NAME OF SUBMITTER:	JEFFREY R. BOUSQUET
SIGNATURE:	/Jeffrey R. Bousquet/
DATE SIGNED:	07/16/2019
Total Attachments: 13 source=P56604_Assignment#page1.tif source=P56604_Assignment#page2.tif source=P56604_Assignment#page3.tif source=P56604_Assignment#page4.tif source=P56604_Assignment#page5.tif source=P56604_Assignment#page6.tif source=P56604_Assignment#page7.tif source=P56604_Assignment#page8.tif source=P56604_Assignment#page9.tif source=P56604_Assignment#page10.tif source=P56604_Assignment#page11.tif source=P56604_Assignment#page12.tif source=P56604_Assignment#page13.tif	

COMBINED INVENTOR'S DECLARATION AND ASSIGNMENT**DECLARATION**

The herein-identified application was made or authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Authorization to Permit Access to Application by Participating Office

☒ If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the herein-identified patent application is filed access to the herein-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the herein-identified patent application is filed to have access to the herein-identified patent application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the herein-identified patent application with respect to: 1) the herein-identified patent application-as-filed; 2) any foreign application to which the herein-identified patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the herein-identified patent application; and 3) any U.S. application-as-filed from which benefit is sought in the herein-identified patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices.

The undersigned hereby authorizes the U.S. attorney or agent appointed herein to accept and follow instructions from either his foreign patent agent or corporate representative, if any, as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned.

Direct Correspondence to: **CUSTOMER NUMBER 07055**

At: Greenblum & Bernstein, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191

Direct Telephone Calls to: Greenblum & Bernstein, P.L.C. (703) 716-1191

ASSIGNMENT

WHEREAS, **Akira SUGIYAMA**, a resident of Tokyo, JAPAN, whose mailing address is c/o THE UNIVERSITY OF TOKYO, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 113-8654 JAPAN, **Hirofumi DOI**, a resident of Chiba, JAPAN, whose mailing address is c/o THE UNIVERSITY OF TOKYO, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 113-8654 JAPAN, **Tatsuhiko KODAMA**, a resident of Tokyo, JAPAN, whose mailing address is c/o THE UNIVERSITY OF TOKYO, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 113-8654 JAPAN, **Tsuyoshi INOUE**, a resident of Osaka, JAPAN, whose mailing address is c/o OSAKA UNIVERSITY, 2-1, Yamadaoka, Suita-shi, Osaka 565-0871 JAPAN, **Eiichi MIZOHATA**, a resident of Osaka, JAPAN, whose mailing address is c/o OSAKA UNIVERSITY, 2-1, Yamadaoka, Suita-shi, Osaka 565-0871 JAPAN, **Tatsuya KAWATO**, a resident of Tokushima, JAPAN, whose mailing address is c/o OSAKA UNIVERSITY, 2-1, Yamadaoka, Suita-shi, Osaka 565-0871 JAPAN, **Tomohiro MESHIZUKA**, a resident of Osaka, JAPAN, whose mailing address is c/o OSAKA UNIVERSITY, 2-1, Yamadaoka, Suita-shi, Osaka 565-0871 JAPAN, **Motomu KANAI**, a resident of Tokyo, JAPAN, whose mailing address is c/o THE UNIVERSITY OF TOKYO, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 113-8654 JAPAN, **Yohei SHIMIZU**, a resident of Tokyo, JAPAN, whose mailing address is c/o THE UNIVERSITY OF TOKYO, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 113-8654 JAPAN, **Noriaki TAKASU**, a resident of Mie, JAPAN, whose mailing address is c/o THE UNIVERSITY OF TOKYO, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 113-8654 JAPAN and **Mari TAKATSU**, a resident of Tokyo, JAPAN, whose mailing address is c/o THE UNIVERSITY OF TOKYO, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 113-8654 JAPAN, hereinafter referred to as the ASSIGNORS, have invented a certain improvement relating to

MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM

for which an application for Letters Patent in the United States entered the National Stage in the United States Patent and Trademark Office on August 17, 2016 and was awarded Application No. **15/119,441**, and which Application is a National Stage of International Application No. PCT/JP2015/054431, filed February 18, 2015.

AND WHEREAS, **SAVID THERAPEUTICS INC.**, a corporation organized and existing under the laws of JAPAN, whose mailing address is 2-1-11, Kachidoki, Chuo-ku, Tokyo 104-0054 JAPAN, hereinafter known as the ASSIGNEE, is desirous of acquiring the entire right, title and interest for the United States in and to said invention and application, including any and all divisions and continuations thereof, and any and all Letters Patent which may be granted thereon, including any and all renewals, reissues, reexaminations, and prolongations thereof.

NOW, THIS WITNESSETH that for good and valuable consideration, the receipt whereof is hereby acknowledged, said ASSIGNORS hereby assign, sell and transfer to said ASSIGNEE, its assigns and legal representatives, the entire and exclusive right, title and interest in and to said invention and application, for the United States including any and all divisions and continuations thereof, and any and all Letters Patent which may be granted therefor and all rights to sue for past and future infringement thereunder, said ASSIGNEE and its assigns and legal representatives to

have, hold, exercise and enjoy the said invention and application, including any and all divisions and continuations thereof, and any and all Letters Patent which may be granted thereon, including any and all renewals, reissues, reexaminations, and prolongations thereof, with all the rights, powers, privileges, and advantages in any ways arising from or pertaining thereto, for and during the term or terms of any and all such Letters Patent when granted, including any and all renewals, reissues, reexaminations, and prolongations thereof, for the use and benefit of said ASSIGNEE and its assigns and legal representatives in as ample and beneficial a manner to all intents and purposes as the said ASSIGNORS might or could have held and enjoyed the same, if this assignment had not been made.

AND said ASSIGNORS hereby agree to execute all papers necessary to file applications in the United States for said invention and to assign the same to said ASSIGNEE, or any assignee acquiring title to said invention, and to execute any other papers that may be needed in connection with filing said application and securing Letters Patent thereon.

AND said ASSIGNORS authorize and request the Commissioner of Patents to issue Letters Patent on said application, and on any and all divisions and continuations thereof, to said ASSIGNEE, its assigns and legal representatives, in accordance herewith.

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)


Akira SUGIYAMA

Oct. 13. 2016
Date

Second Witness (Optional):

(Name)


(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)



Hirofumi DOI

Oct. 18th 2016
Date

Second Witness (Optional):

(Name)

(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)

Tatsuhiko Kodama

Tatsuhiko KODAMA

Oct. 13, 2016

Date

Second Witness (Optional):

(Name)

(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)

Tsuyoshi Inoue (井上 豊)

Tsuyoshi INOUE

Oct. 15, 2016

Date

Second Witness (Optional):

(Name)

(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)


Eiichi MIZOHATA

Date

Oct 14, 2016

Second Witness (Optional):

(Name)

(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)

Tatsuya KAWATO
Tatsuya KAWATO
14/10/2016
Date

Second Witness (Optional):

(Name)

(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)

Tomohiro MESHIZUKA

Tomohiro MESHIZUKA

Oct 17, 2016
Date

Second Witness (Optional):

(Name)

(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)



Motomu KANAI

Oct. 14, 2016

Date

Second Witness (Optional):

(Name)

(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)

Y. Shimizu

Yohei SHIMIZU

10.14.2016.

Date

Second Witness (Optional):

(Name)

(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)

Noriaki TAKASU

Noriaki TAKASU

2016. 10. 14

Date

Second Witness (Optional):

(Name)

(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR(S), on the respective date(s) indicated below.

First Witness (Optional):

(Name)

(Date)


Mari TAKATSU

October 18, 2016
Date

Second Witness (Optional):

(Name)

(Date)

{P50788 02853434.DOC}